| Trial ID: | L2034 |
| Source ID: | NCT00467376
|
| Associated Drug: |
Insulin Glulisine
|
| Title: |
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Insulin Glulisine|DRUG: Lispro|DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: Hypoglycemic episodes, From the beginning to end of the study|Change in HbA1c, From baseline to endpoint|Adverse events, From the beginning to the end of study | Secondary: Change in HbA1c, From baseline to weeks 12|blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus., from baseline to week 12
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
485
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-01
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2009-09-15
|
| Locations: |
Sanofi-Aventis, Beijing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00467376
|
